Key Points President Trump's tariffs could erode healthcare companies' profits, but some may perform well regardless.Eli Lilly and Novartis have taken steps to mitigate the potential impact. Both ...

Analysts are all over Eli Lilly, and most suggest a "Moderate Buy." Sixteen analysts recommend buying, while three say "hold.

FBCG, a large-cap growth ETF, excels in bullish markets but struggles in downturns. Learn why it's rated Hold amid current ...

The Global Bipolar Disorder Market report forecasts significant growth from 2025 to 2035, driven by rising prevalence, awareness, and pharmacotherapy ...